A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).

NCT06997159 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Localized Cutaneous Leishmaniasis

Interventions

DRUG: LXE408
DRUG: Miltefosine 50 MG Oral Capsule [Impavido]
DRUG: Placebo to LXE408

Sponsor

Drugs for Neglected Diseases

Collaborators

[object Object]